1. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
- Author
-
McGarry, Andrew, McDermott, Michael, Kieburtz, Karl, de Blieck, Elisabeth A, Beal, Flint, Marder, Karen, Ross, Christopher, Shoulson, Ira, Gilbert, Peter, Mallonee, William M, Guttman, Mark, Wojcieszek, Joanne, Kumar, Rajeev, LeDoux, Mark S, Jenkins, Mary, Rosas, H Diana, Nance, Martha, Biglan, Kevin, Como, Peter, Dubinsky, Richard M, Shannon, Kathleen M, O'Suilleabhain, Padraig, Chou, Kelvin, Walker, Francis, Martin, Wayne, Wheelock, Vicki L, McCusker, Elizabeth, Jankovic, Joseph, Singer, Carlos, Sanchez-Ramos, Juan, Scott, Burton, Suchowersky, Oksana, Factor, Stewart A, Higgins, Donald S, Molho, Eric, Revilla, Fredy, Caviness, John N, Friedman, Joseph H, Perlmutter, Joel S, Feigin, Andrew, Anderson, Karen, Rodriguez, Ramon, McFarland, Nikolaus R, Margolis, Russell L, Farbman, Eric S, Raymond, Lynn A, Suski, Valerie, Kostyk, Sandra, Colcher, Amy, Seeberger, Lauren, Epping, Eric, Esmail, Sherali, Diaz, Nancy, Fung, Wai Lun Alan, Diamond, Alan, Frank, Samuel, Hanna, Philip, Hermanowicz, Neal, Dure, Leon S, and Cudkowicz, Merit
- Subjects
Clinical Research ,Clinical Trials and Supportive Activities ,Huntington's Disease ,Nutrition ,Neurodegenerative ,Neurosciences ,Brain Disorders ,Rare Diseases ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Australia ,Canada ,Double-Blind Method ,Female ,Humans ,Huntington Disease ,International Cooperation ,Male ,Middle Aged ,Proportional Hazards Models ,Retrospective Studies ,Treatment Outcome ,Ubiquinone ,United States ,Vitamins ,Huntington Study Group 2CARE Investigators and Coordinators ,Clinical Sciences ,Cognitive Sciences ,Neurology & Neurosurgery - Abstract
ObjectiveTo test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow the progressive functional decline of HD.MethodsWe performed a multicenter randomized, double-blind, placebo-controlled trial. Patients with early-stage HD (n = 609) were enrolled at 48 sites in the United States, Canada, and Australia from 2008 to 2012. Patients were randomized to receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was the change from baseline to month 60 in Total Functional Capacity score (for patients who survived) combined with time to death (for patients who died) analyzed using a joint-rank analysis approach.ResultsAn interim analysis for futility revealed a conditional power of
- Published
- 2017